BridgeBio Oncology Therapeutics Inc.

BBOTNASDAQHealthcare● Active

$7.78

$-0.03(-0.38%)

Market Cap$623233269

P/E Ratio—

52W High$14.87

52W Low$7.6

Avg Volume346K

Open$8.10

Beta0.29

Overview

BridgeBio Oncology Therapeutics Inc. (BBOT) Insider Trading

Form 4 buy vs sell counts, ratio, and sentiment — switch this quarter or last 12 months; chart and transactions below.

SEC EDGAR · FMP · BBOT · as of Jun 8, 2026

Activity summary

Buy transactions

P-Purchase only

Sell transactions

12 Months

Buy/Sell ratio

0.00

Buy/Sell (by trades)

Overall sentiment

NEUTRAL

↑ Buy 0%Active transactions only · RSU vesting excluded100% Sell ↓

BridgeBio Oncology Therapeutics Inc. insiders have shown mixed buying and selling activity over the past 12 Months.

▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · Buy = P-Purchase only · Sell = S-Sale only

As of Jun 8, 2026

BBOT insider buying and selling by quarter

BBOT insider selling · BBOT insider buying stocks · quarterly insider activity

Total insider buying (incl. awards)Total insider selling

17.3M8.7M0

2025 Q3

2025 Q4

2026 Q1

2026 Q2

Mobile shows last 4Q · Desktop shows full 8Q

▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · last 8 quarters

As of Jun 8, 2026

Active insiders

Most active in past 12 months · BBOT ceo insider trading

Showing all insiders · Click a card to filter the transactions table below

▸ Aggregated from reportingName · top 5 by trade count (12M) · no extra API

Recent insider transactions

BBOT executive sell shares · BBOT board member insider trading · BBOT insider trading SEC filing

Showing 18 most recent · Common Stock · Form 4 only

Scroll horizontally to see all columns

Date	Insider	Type	Shares	Price	Value	After trans.	Filing
Apr 1, 2026	Ben Yong Chief Med & Dev Officer	Other	1,047	$9.03	$9K	45,623	Form 4
Apr 1, 2026	Beltran Pedro President and CEO · Director	Other	1,047	$9.03	$9K	45,623	Form 4
Apr 1, 2026	Mehra Uneek other: Former Officer	Other	524	$9.03	$5K	22,806	Form 4
Mar 10, 2026	Mehra Uneek CFO	Award	23,330	—	—	23,330	Form 4
Mar 10, 2026	Beltran Pedro Chief Scientific Officer	Award	46,670	—	—	46,670	Form 4
Mar 10, 2026	Ben Yong Chief Med & Dev Officer	Award	46,670	—	—	46,670	Form 4
Oct 10, 2025	BridgeBio Pharma LLC 10 percent owner	Other	784,720	—	—	14,589,846	Form 4
Aug 11, 2025	Chen Bihua Director	Award	284,571	—	—	5,952,356	Form 4
Aug 11, 2025	Chen Bihua Director	Award	5,598,425	$10.72	$60.00M⚡	5,667,785	Form 4
Aug 11, 2025	Chen Bihua Director	Option	4,172,126	$0.00	$417	4,681,126	Form 4
Aug 11, 2025	Chen Bihua Director	Other	152,940	—	—	4,528,186	Form 4
Aug 11, 2025	Chen Bihua Director	Award	1,762,760	—	—	3,305,470	Form 4
Aug 11, 2025	Chen Bihua Director	Award	760,496	$10.72	$8.15M⚡	2,187,536	Form 4
Aug 11, 2025	Chen Bihua Director	Award	1,905,046	—	—	1,905,046	Form 4
Aug 11, 2025	Chen Bihua Director	Award	639,110	$10.72	$6.85M⚡	1,542,710	Form 4
Aug 11, 2025	Holman Albert A III Director	Option	30,000	—	—	30,000	Form 4
Aug 11, 2025	McKenna Mark C. Director	Option	30,000	—	—	30,000	Form 4
Aug 11, 2025	Schmid John P. Director	Option	30,000	—	—	30,000	Form 4

Ben Yong

Chief Med & Dev Officer

Other

Date

Apr 1

1,047

Price

$9.03

Value

$9K

View Form 4 on SEC.gov

Beltran Pedro

President and CEO · Director

Other

Date

Apr 1

1,047

Price

$9.03

Value

$9K

View Form 4 on SEC.gov

Mehra Uneek

other: Former Officer

Other

Date

Apr 1

524

Price

$9.03

Value

$5K

View Form 4 on SEC.gov

Mehra Uneek

CFO

Award

Date

Mar 10

23,330

Price

—

Value

—

View Form 4 on SEC.gov

Beltran Pedro

Chief Scientific Officer

Award

Date

Mar 10

46,670

Price

—

Value

—

View Form 4 on SEC.gov

Ben Yong

Chief Med & Dev Officer

Award

Date

Mar 10

46,670

Price

—

Value

—

View Form 4 on SEC.gov

BridgeBio Pharma LLC

10 percent owner

Other

Date

Oct 10

784,720

Price

—

Value

—

View Form 4 on SEC.gov

Chen Bihua

Director

Award

Date

Aug 11

284,571

Price

—

Value

—

View Form 4 on SEC.gov

Chen Bihua

Director

Award

Date

Aug 11

5,598,425

Price

$10.72

Value

$60.00M ⚡

View Form 4 on SEC.gov

Chen Bihua

Director

Option

Date

Aug 11

4,172,126

Price

$0.00

Value

$417

View Form 4 on SEC.gov

Chen Bihua

Director

Other

Date

Aug 11

152,940

Price

—

Value

—

View Form 4 on SEC.gov

Chen Bihua

Director

Award

Date

Aug 11

1,762,760

Price

—

Value

—

View Form 4 on SEC.gov

Chen Bihua

Director

Award

Date

Aug 11

760,496

Price

$10.72

Value

$8.15M ⚡

View Form 4 on SEC.gov

Chen Bihua

Director

Award

Date

Aug 11

1,905,046

Price

—

Value

—

View Form 4 on SEC.gov

Chen Bihua

Director

Award

Date

Aug 11

639,110

Price

$10.72

Value

$6.85M ⚡

View Form 4 on SEC.gov

Holman Albert A III

Director

Option

Date

Aug 11

30,000

Price

—

Value

—

View Form 4 on SEC.gov

McKenna Mark C.

Director

Option

Date

Aug 11

30,000

Price

—

Value

—

View Form 4 on SEC.gov

Schmid John P.

Director

Option

Date

Aug 11

30,000

Price

—

Value

—

View Form 4 on SEC.gov

▸ Source: SEC EDGAR · Form 4 filings · ⚡ = value ≥ $1M · Award/Option price shows —

About BBOT insider trading

BBOT insider trades

BridgeBio Oncology Therapeutics Inc. (BBOT) insider trading data is sourced from SEC Form 4 filings submitted by corporate insiders, including Chen Bihua (Director), Ben Yong (Chief Med & Dev Officer), Beltran Pedro (President and CEO · Director). Over the past 12 months, 5 insiders have filed transactions with the SEC. BBOT insiders have been mixed buying and selling, which may reflect pre-scheduled Rule 10b5-1 plan executions.

For BridgeBio Oncology Therapeutics Inc.'s institutional ownership breakdown and insider ownership percentage, see the Ownership tab → Ownership tab →

Buy/Sell signal logic

acquisitionOrDisposition field:

A = Acquisition (buy) · D = Disposition (sell)

RSU vesting (M-Exempt) excluded from sentiment

Form 4SEC filing required within 2 business days of any insider transaction

10b5-1Pre-scheduled trading plan that allows insiders to sell on autopilot

Open MktDirect purchase or sale on the open market (excludes awards, options)

Ownership SEC filings Financial statements Price history Forecast & ratings Earnings

Frequently asked questions

BBOT insider trading · 5 questions

The insiders of BridgeBio Oncology Therapeutics Inc. (BBOT) include executives and directors such as Chen Bihua (Director), Ben Yong (Chief Med & Dev Officer), Beltran Pedro (President and CEO · Director), among others. Over the past 12 months, 5 insiders have filed Form 4 transactions with the SEC. Insider transactions are required to be reported within 2 business days of the trade date.

BBOT board member insider tradingwho are BBOT insidersBBOT insider rosterBridgeBio Oncology Therapeutics Inc. executives insider activity

▸ Source: FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · acquisitionOrDisposition A=Buy, D=Sell · RSU vesting (M-Exempt) excluded from sentiment bar · As of Jun 8, 2026